Total for the last 12 months
number of access : ?
number of downloads : ?
ID 118258
Title Alternative
血漿Heparin Cofactor II活性は2型糖尿病患者における非アルコール性脂肪性肝疾患肝線維化と逆相関する
Heparin Cofactor II and NAFLD in T2DM
Author
Uemoto, Ryoko Tokushima University
Sekine, Akiko Tokushima University
Mitsui, Yukari Tokushima University
Masuda, Shiho Tokushima University
Otoda, Toshiki Tokushima University
Honda, Soichi Minami Municipal National Insurance Hospital
Kondo, Akira Kondo Naika Hospital
Keywords
ヘパリンコファクターII
プロテアーゼ活性化受容体
糖尿病
NAFLD
横断研究
Thrombin
Protease-activated receptors
Heparin cofactor II
T2DM
Content Type
Thesis or Dissertation
Description
Aims: Thrombin exerts various pathophysiological functions by activating protease-activated receptors (PARs), and thrombin-induced activation of PARs promotes the development of non-alcoholic fatty liver disease (NAFLD). Since heparin cofactor II (HCII) specifically inactivates thrombin action, we hypothesized that plasma HCII activity correlates with the severity of NAFLD.
Methods: A cross-sectional study was conducted. Plasma HCII activity and noninvasive clinical markers of hepatic fibrosis including fibrosis-4 (FIB-4) index, NAFLD fibrosis score (NFS) and aspartate aminotransferase-to-platelet ratio index (APRI) were determined in 305 Japanese patients with type 2 diabetes mellitus (T2DM). The relationships between plasma HCII activity and the clinical markers were statistically evaluated.
Results: Multiple regression analysis including confounding factors showed that plasma HCII activity independently contributed to decreases in FIB-4 index (p<0.001), NFS (p<0.001) and APRI (p=0.004). In addition, logistic regression analysis for the prevalence of advanced hepatic fibrosis defined by the cutoff points of the clinical scores showed that plasma HCII activity was the sole and common negative factor for prevalence of advanced hepatic fibrosis (FIB-4 index: p=0.002, NFS: p=0.026 and APRI: p=0.012).
Conclusions: Plasma HCII activity was inversely associated with clinical hepatic fibrosis indices including FIB-4 index, NFS and APRI and with the prevalence of advanced hepatic fibrosis in patients with T2DM. The results suggest that HCII can serve as a novel biomarker for assessment of hepatic fibrosis of NAFLD in patients with T2DM.
Journal Title
Journal of Atherosclerosis and Thrombosis
ISSN
18803873
13403478
Publisher
Japan Atherosclerosis Society
Volume
30
Issue
8
Start Page
871
End Page
883
Published Date
2023-08-01
Remark
内容要旨・審査要旨・論文本文の公開
本論文は,著者Tomoyo Haraの学位論文として提出され,学位審査・授与の対象となっている。
Rights
This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.( https://creativecommons.org/licenses/by-nc-sa/4.0/deed.ja )
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
ETD
MEXT report number
甲第3689号
Diploma Number
甲医第1554号
Granted Date
2023-03-23
Degree Name
Doctor of Medical Science
Grantor
Tokushima University
departments
Medical Sciences
University Hospital
Institute of Advanced Medical Sciences
Oral Sciences